DE602005025977D1 - Kristalline form des ibandronat-natriums und herstellungsverfahren dafür - Google Patents

Kristalline form des ibandronat-natriums und herstellungsverfahren dafür

Info

Publication number
DE602005025977D1
DE602005025977D1 DE602005025977T DE602005025977T DE602005025977D1 DE 602005025977 D1 DE602005025977 D1 DE 602005025977D1 DE 602005025977 T DE602005025977 T DE 602005025977T DE 602005025977 T DE602005025977 T DE 602005025977T DE 602005025977 D1 DE602005025977 D1 DE 602005025977D1
Authority
DE
Germany
Prior art keywords
ibandronate sodium
crystalline form
manufacturing
ray
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602005025977T
Other languages
German (de)
English (en)
Inventor
Revital Lifshitz-Liron
Thomas Bayer
Judith Aronhime
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35968334&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602005025977(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of DE602005025977D1 publication Critical patent/DE602005025977D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Liquid Crystal Substances (AREA)
  • Artificial Filaments (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Secondary Cells (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Battery Electrode And Active Subsutance (AREA)
DE602005025977T 2004-08-23 2005-08-23 Kristalline form des ibandronat-natriums und herstellungsverfahren dafür Expired - Lifetime DE602005025977D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60402604P 2004-08-23 2004-08-23
US69086705P 2005-06-16 2005-06-16
PCT/US2005/030500 WO2006024024A2 (en) 2004-08-23 2005-08-23 Solid and crystalline ibandronate sodium and processes for preparation thereof

Publications (1)

Publication Number Publication Date
DE602005025977D1 true DE602005025977D1 (de) 2011-03-03

Family

ID=35968334

Family Applications (2)

Application Number Title Priority Date Filing Date
DE602005025977T Expired - Lifetime DE602005025977D1 (de) 2004-08-23 2005-08-23 Kristalline form des ibandronat-natriums und herstellungsverfahren dafür
DE202005021414U Expired - Lifetime DE202005021414U1 (de) 2004-08-23 2005-08-23 Festes und kristallines Ibandronat-Natrium

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE202005021414U Expired - Lifetime DE202005021414U1 (de) 2004-08-23 2005-08-23 Festes und kristallines Ibandronat-Natrium

Country Status (12)

Country Link
US (1) US7563918B2 (enExample)
EP (2) EP1930011B1 (enExample)
JP (1) JP4559431B2 (enExample)
KR (2) KR20090120011A (enExample)
CN (1) CN101022812A (enExample)
AT (2) ATE520406T1 (enExample)
CA (1) CA2576659A1 (enExample)
DE (2) DE602005025977D1 (enExample)
ES (1) ES2358269T3 (enExample)
IL (1) IL181298A (enExample)
PT (2) PT1930011E (enExample)
WO (1) WO2006024024A2 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE044822T2 (hu) 2003-09-12 2019-11-28 Amgen Inc Cinakalcet HCl gyors feloldódású készítménye
AU2006210008B2 (en) * 2005-02-01 2009-10-08 F. Hoffmann-La Roche Ag Ibandronate polymorph B
CA2594802C (en) * 2005-02-01 2012-11-27 Uwe Eiermann Ibandronate polymorph a
WO2007074475A2 (en) * 2005-12-27 2007-07-05 Natco Pharma Limited Novel polymorphic forms of ibandronate
EP2046342A4 (en) * 2006-07-28 2011-05-04 Reddys Lab Ltd Dr CRYSTALLINE FORM WITH IBANDRONIC ACID AND PROCESS FOR PREPARING THE SAME
JP2009516004A (ja) * 2006-11-16 2009-04-16 テバ ファーマシューティカル インダストリーズ リミティド イバンドロン酸ナトリウムの結晶形態
CA2570949A1 (en) * 2006-12-12 2008-06-12 Apotex Pharmachem Inc. Ibandronate sodium propylene glycol solvate and processes for the preparation thereof
MX2009010850A (es) 2007-04-11 2009-11-02 Hoffmann La Roche Sintesis de ibandronato en multiples etapas.
WO2008131160A1 (en) * 2007-04-19 2008-10-30 Dr. Reddy's Laboratories Ltd. Ibandronate sodium polymorphs
US20090042839A1 (en) * 2007-08-09 2009-02-12 Sharon Avhar-Maydan Crystalline forms of ibandronate sodium
WO2009053445A2 (en) * 2007-10-26 2009-04-30 Chemo Ibérica, S.A. Polymorphic forms of ibandronate sodium and processes for preparation thereof
EP2128166A1 (en) 2008-05-20 2009-12-02 Chemo Ibérica, S.A. Polymorphic forms of Ibandronate sodium and processes for preparation thereof
US20090118239A1 (en) * 2007-11-05 2009-05-07 Teva Pharmaceutical Industries Ltd. Amorphous and crystalline forms of ibandronate disodium
EP2180003A1 (en) 2008-10-21 2010-04-28 Zentiva, k.s. Preparation of ibandronate trisodium
SG173619A1 (en) 2009-02-13 2011-09-29 Boehringer Ingelheim Int Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof
US9192316B2 (en) 2009-05-15 2015-11-24 Nox Medical Systems and methods using flexible capacitive electrodes for measuring biosignals
WO2011016738A1 (en) 2009-08-05 2011-02-10 Zaklady Farmaceutyczne Polpharma Sa A process for the synthesis of 1-hydroxy-3-(n-methylpentylamino) propylidene bisphosphonic acid monosodium salt, monohydrate
EA032868B1 (ru) 2010-01-27 2019-07-31 Вайв Хелткер Компани Комбинация для лечения вич-инфекции
CA2833111C (en) 2010-06-25 2018-08-21 Kormakur Hlini Hermannsson Biometric belt connector
JP6121421B2 (ja) 2010-09-03 2017-04-26 バルネバ オーストリア ジーエムビーエイチ Ｃ．ディフィシルの毒素ａおよび毒素ｂタンパク質の単離ポリペプチドならびにその使用
UY33937A (es) 2011-03-07 2012-09-28 Boehringer Ingelheim Int Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
WO2013179305A1 (en) * 2012-06-01 2013-12-05 Hetero Research Foundation Ibandronate sodium solid dispersion
WO2014170909A2 (en) 2013-04-01 2014-10-23 Hetero Research Foundation Process for pomalidomide
EP3065638B1 (en) 2013-11-06 2024-01-10 Nox Medical ehf. Method, apparatus, and system for measuring respiratory effort
SG10202012791TA (en) 2013-11-15 2021-01-28 Akebia Therapeutics Inc Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
EP3500155B1 (en) 2016-08-19 2024-10-02 Nox Medical Method, system, and computer program for measuring respiratory effort of a subject
EP3629893A1 (en) 2017-06-02 2020-04-08 Nox Medical ehf. Coherence-based method, apparatus, and system for identifying corresponding signals of a physiological study
EP3678543A1 (en) 2017-09-08 2020-07-15 Nox Medical System and method for non-invasively determining an internal component of respiratory effort

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3623397A1 (de) * 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
JP2639721B2 (ja) 1988-12-27 1997-08-13 富士重工業株式会社 内燃機関の燃焼室
US5652227A (en) * 1995-01-30 1997-07-29 Teronen; Olli Pekka Inhibition of the degradation of connective tissue matrix protein components in mammals
DE19637890A1 (de) * 1996-09-17 1998-03-19 Max Planck Gesellschaft Biphosphonat-Liposomen
DE19828450A1 (de) * 1998-06-26 1999-12-30 Hassan Jomaa Bisphosphonsäuren und deren Derivate enthaltende Arzneimittel zur Prophylaxe und zur Behandlung von Autoimmunkrankheiten sowie von Allergien
EP0998933A1 (de) * 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Verfahren zur Herstellung von bisphosphonathaltigen pharmazeutischen Zusammensetzungen zur oralen Applikation
EP0998932A1 (de) * 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung
CN1202828C (zh) * 1999-05-21 2005-05-25 诺瓦提斯公司 二膦酸在制备抑制或逆转血管发生的药物中的用途
US6677320B2 (en) * 2000-01-20 2004-01-13 Hoffmann-La Roches Inc. Parenteral bisphosphonate composition with improved local tolerance
ES2254410T3 (es) * 2000-05-05 2006-06-16 F. Hoffmann-La Roche Ag Composicion farmaceutica como gel para administracion subcutanea que comprende acidos bisfosfonicos o sus sales.
ES2247123T7 (es) * 2000-06-20 2013-03-01 Novartis Ag Método para administrar bisfosfonatos
GB0029111D0 (en) * 2000-11-29 2001-01-10 Novartis Ag Organic compounds
MXPA02001219A (es) * 2001-02-01 2005-06-06 Riderway Corp Composicion farmaceutica liquida para el tratamiento de enfermedades oseas.
ITMI20020908A1 (it) 2002-04-29 2003-10-29 Chemi Spa Processo di preparazione di sodio alendronato
PT1880744E (pt) * 2002-05-10 2015-02-13 Hoffmann La Roche Ácidos bisfosfónicos para o tratamento e a prevenção da osteoporose
US20050287135A1 (en) * 2002-05-17 2005-12-29 Wyeth Injectable solid hyaluronic acid carriers for delivery of osteogenic proteins
PL212072B1 (pl) * 2002-12-20 2012-08-31 Hoffmann La Roche Tabletka zawierająca jako substancję czynną do 250 mg kwasu ibandronowego oraz sposób jej wytwarzania
EP2206717B1 (en) * 2003-12-23 2013-03-27 Alchymars S.p.A. A process for the preparation of alkyl- and aryl-diphosphonic acids and salts thereof
WO2006002348A2 (en) * 2004-06-23 2006-01-05 Teva Pharmaceutical Industies Ltd. Solid and crystalline ibandronic acid
AU2006210008B2 (en) 2005-02-01 2009-10-08 F. Hoffmann-La Roche Ag Ibandronate polymorph B
CA2594802C (en) 2005-02-01 2012-11-27 Uwe Eiermann Ibandronate polymorph a
WO2007074475A2 (en) 2005-12-27 2007-07-05 Natco Pharma Limited Novel polymorphic forms of ibandronate

Also Published As

Publication number Publication date
CA2576659A1 (en) 2006-03-02
KR20090120011A (ko) 2009-11-23
US20070179119A1 (en) 2007-08-02
IL181298A0 (en) 2007-07-04
EP1930011A2 (en) 2008-06-11
PT1713489E (pt) 2011-03-03
EP1713489B1 (en) 2011-01-19
CN101022812A (zh) 2007-08-22
JP2007512237A (ja) 2007-05-17
EP1713489A2 (en) 2006-10-25
WO2006024024A3 (en) 2006-06-29
WO2006024024A2 (en) 2006-03-02
EP1930011B1 (en) 2011-08-17
KR20070043043A (ko) 2007-04-24
IL181298A (en) 2011-04-28
US7563918B2 (en) 2009-07-21
ATE495747T1 (de) 2011-02-15
JP4559431B2 (ja) 2010-10-06
ATE520406T1 (de) 2011-09-15
PT1930011E (pt) 2011-09-16
EP1930011A3 (en) 2008-06-18
ES2358269T3 (es) 2011-05-09
DE202005021414U1 (de) 2008-03-20

Similar Documents

Publication Publication Date Title
DE602005025977D1 (de) Kristalline form des ibandronat-natriums und herstellungsverfahren dafür
JO2793B1 (en) The new crystalline form 5 of agomelatine, its preparation process and the pharmaceutical ingredients it contains
UA86595C2 (ru) Гамма-кристаллическая форма гидрохлорида ивабрадина, способ ее получения и фармацевтическая композиция, которая ее содержит
TW200512206A (en) 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amion]-propionic acid ethylester-methanesulfonate and its use as a medicament
TW200716558A (en) Heteroaroyl-substituted serineamides
IL190137A (en) Lacquinimod crystalline mixtures, pharmaceutical compositions containing them and ways to prepare them
BG107532A (en) Novel alpha chrystalline form of perindopril tert-butylamine salts, preparation method and pharmaceutical compositions containing same
GEP20084452B (en) Sulfonamide derivatives for the treatment of diseases
MY141306A (en) New crystalline form iv of agomelatine, a process for its preparation and pharmaceutical compositions containing it
MY142856A (en) New crystalline form iii of agomelatine, a process for its preparation and pharmaceutical compositions containing it
MX2008002061A (es) Derivados de tiazolil piperidina utiles como moduladores del receptor h3.
GEP20125433B (en) α CRYSTALLINE FORM OF THE ARGININE SALT OF PERINDOPRIL, PROCESS FOR PREPARING IT, AND PHARMACEUTICAL COMPOSITIONS COMPRISING IT
MY143557A (en) Beta-crystalline form of perindopril arginine salt, process for its preparation, and pharmaceutical compositions containing it
TW200740764A (en) Pyrazolone derivatives
TW200800993A (en) Organic compounds
TW200626581A (en) Compounds, compositions containing them, preparation thereof and uses thereof
EA200900936A1 (ru) Аморфные и кристаллические формы ривастигмина гидротартрата
GEP20084470B (en) New phenylpyridinylpiperazine compounds, a process for their preparation and pharmaceutical compositions containing them
TW200730498A (en) Compounds
TNSN05077A1 (en) New y crystalline form of perindopril tert-butylamine salt, a process for its preparation and pharmaceutical compositions containing it
MY138209A (en) New (y) crystalline form of perindopril tert-butylamine salt, a process for its preparation and pharmaceutical compositions containing it.
TW200738606A (en) Thioamide compounds for combating animal pest
TNSN05076A1 (en) New alpha crystalline form of perindopril tert-butylamine salt, a process for its preparation and pharmaceutical compositions containing it
TNSN05078A1 (en) New beta crystalline form of perindopril tert-butylamine salt, a process for its preparation and pharmaceutical compositions containing it
GEP20094652B (en) New cyrstalline form v of agomelatine, a process for its preparation and pharmaceutical compositions containing it